China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

China’s Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes.
The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday.
Innovent, which is based in Suzhou in China’s eastern Jiangsu…

المصدر: South China Morning Post